PMVP
vs
S&P 500
PMVP
S&P 500
Over the past 12 months, PMVP has underperformed S&P 500, delivering a return of -18% compared to the S&P 500's +14% growth.
Stocks Performance
PMVP vs S&P 500
Performance Gap
PMVP vs S&P 500
Performance By Year
PMVP vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
PMV Pharmaceuticals Inc
Glance View
PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. The company is headquartered in Cranbury, New Jersey and currently employs 54 full-time employees. The company went IPO on 2020-09-25. The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The firm is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.